“BridgeBio Pharma is undergoing a significant transformation as Attruby (acoramidis) establishes itself as a leading therapy in transthyretin amyloid cardiomyopathy (ATTR-CM), driving robust revenue growth and market share gains. With over 7,800 unique patient prescriptions and strong prescriber adoption by early 2026, Attruby’s near-complete TTR stabilization profile positions it as a first-choice option. Meanwhile, the company’s late-stage pipeline advances—with planned NDA submissions for BBP-418 in LGMD2I/R9 and encaleret in ADH1 in the first half of 2026, positive Phase 3 results for infigratinib in achondroplasia, and emerging programs like a TTR amyloid depleter—signal multiple potential catalysts that could expand BridgeBio’s commercial footprint and shift investor focus from development risks to revenue generation and long-term profitability.”
How The BridgeBio Pharma (BBIO) Narrative Is Shifting With Attruby And Late Stage Pipeline
BridgeBio Pharma (Nasdaq: BBIO) has evolved rapidly from a development-focused biotech into a commercial-stage player with meaningful revenue traction. The catalyst is Attruby (acoramidis), the oral near-complete transthyretin (TTR) stabilizer approved by the FDA in late 2024 for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization.
Attruby’s differentiation stems from its ability to achieve ≥90% TTR stabilization, the highest on the market, leading to rapid clinical benefits observed within one month in trials. This profile has fueled its adoption in a competitive ATTR-CM landscape dominated by established stabilizers.
Commercial momentum has accelerated markedly. In 2025, Attruby generated full-year net product revenue of $362.4 million, with Q4 alone contributing $146.0 million—a 35% sequential increase. By December 31, 2025, the drug had captured more than 25% market share among new patient starts (MBRX). As of February 20, 2026, 7,804 unique patient prescriptions had been written by 1,856 unique prescribers, reflecting strong repeat prescribing, patient persistence, and preference among newly diagnosed cases.
This uptake highlights Attruby’s real-world performance aligning with Phase 3 ATTRibute-CM data, where it demonstrated significant reductions in all-cause mortality and cardiovascular events, including in variant ATTR-CM subpopulations like V142I (V122I). Additional data presentations at major congresses, including upcoming updates at the American College of Cardiology sessions in March 2026, continue to reinforce its edge.
The Attruby launch has reshaped perceptions of BridgeBio, shifting the narrative toward sustainable revenue growth and cash flow improvement. Management anticipates steady cash burn through 2026 before declines, with a goal of transitioning to significant cash generation by 2028 and targeting substantial profitability.
Beyond Attruby, BridgeBio’s late-stage pipeline adds depth and multiple near-term value drivers, diversifying away from single-product reliance.
Key late-stage candidates include:
BBP-418 for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) : The Phase 3 FORTIFY trial’s interim analysis showed broad benefits across endpoints, including a statistically significant and clinically meaningful 2.6-point improvement on the North Star Assessment for Dysferlinopathy (NSAD) versus placebo at 12 months. Benefits were consistent in subgroups, with reductions in creatine kinase and gains in ambulatory and pulmonary function. The FDA recommended pursuing traditional full approval based on these data. BridgeBio plans an NDA submission in the first half of 2026, targeting a potential U.S. launch in late 2026 or early 2027.
Encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1) : Positive Phase 3 CALIBRATE results support an NDA filing in the first half of 2026, following a successful pre-NDA meeting with the FDA. Over 1,700 unique ADH1 patients have been identified since late 2023, underscoring unmet need. A pediatric registrational trial began in Q1 2026, with additional studies in chronic hypoparathyroidism planned. Launch is anticipated in late 2026 or early 2027.
Infigratinib for Achondroplasia : The Phase 3 PROPEL 3 trial delivered positive topline results, marking the first statistically significant improvements in body proportionality in children with this condition. An NDA submission is targeted for the second half of 2026.
These programs represent high-conviction assets in rare genetic diseases, each with orphan designations and clear regulatory paths.
BridgeBio is also advancing innovative approaches in ATTR-CM, including a new TTR amyloid depleter antibody program aimed at disease reversal, with clinical entry expected between 2027 and 2028.
With cash and equivalents around $587.5 million at the end of 2025, the company maintains a solid balance sheet to support pipeline execution while Attruby ramps.
The shifting narrative for BridgeBio centers on execution: Attruby’s commercial success validates the platform, while late-stage catalysts in 2026 could unlock additional revenue streams and broaden the company’s impact in genetic diseases.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial advice, or any form of recommendation. Investing in biotech stocks involves significant risk, including potential loss of principal. Always conduct your own research or consult a qualified advisor.